April 27, 2015 — Blue Ridge Cancer Care (BRCC) recently announced it is now offering radiation clinical trials to cancer patients in Southwest Virginia. These advanced radiation-focused clinical trials give cancer patients access to cutting-edge therapies that could potentially increase cure rates and improve quality of life while providing the opportunity to participate in the development of future treatments.
BRCC is a 19-physician privately-owned practice specializing in the diagnosis and treatment of cancer and an affiliate of The US Oncology Network. The trials are a collaborative effort among BRCC, NRG Oncology and US Oncology Research. BRCC is currently conducting several radiation clinical trials at the Carilion Clinic Cancer Center where eligible patients are now being enrolled.
“Very few cancer centers in the country offer these cutting-edge radiation trials,” said David Buck, M.D., radiation oncologist at Blue Ridge Cancer Care. “Bringing these innovative trials to our practice provides us with a whole new level of advanced, experimental treatment options we can offer our patients, while allowing them to receive these investigational treatments in their hometown, close to their family and friends in a comfortable, outpatient setting.”
With the addition of these novel trials, BRCC’s presence is expanding in Southwest Virginia, providing referring physicians the opportunity to send their patients to a facility closer to the patient’s home. Urologists will be especially interested in the new radiation trials being offered, as many promising trials for prostate cancer are currently available and others are in development.
With one of the largest and most active clinical research programs in Southwest Virginia, Blue Ridge Cancer Care offers Phase II, III and IV clinical trials through its affiliation with US Oncology Research, one of the nation’s largest networks of community-based cancer investigators and clinical staff.
By collaborating with US Oncology Research and NRG Oncology, Blue Ridge Cancer Care can offer patients some of the most advanced radiotherapy trials in the nation, further expanding and enhancing its extensive research program. Supported by the expertise of US Oncology Research, BRCC also has access to comprehensive protocols, procedures and guidelines to help ensure that patient safety and quality assurance remain top priorities during these novel treatments.
“Many technological innovations are emerging in radiation oncology that can potentially enhance care and help patients achieve optimal outcomes,” Buck noted. “These advanced trials investigating new treatment options can provide benefits to patients who participate and also give us a way to evaluate how well the treatments work so others may benefit.”
For more information: www.blueridgecancercare.com